secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2023-04-06T23:59:59+00:00
Accession:  0001493152-23-011292
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte raises ~$13.5M in offering of 45.5M shares at $0.302-$0.354
--------------------------------------------------------------------

- Net proceeds of ~$13.5M after $250K advisory fee and other expenses.
- ~$1.1M used to redeem Series A Preferred stock; remainder for working capital and product commercialization.
- Broadwood Partners (largest shareholder) and board members participated as insiders at $0.35440 per share.
- Offering conducted as takedown from existing S-3 shelf registration statement declared effective June 2021.
- Company intends to use funds to support VitaGraft, DetermaIO, and DetermaCNI development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223011292/0001493152-23-011292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223011292/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-011292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer